221 related articles for article (PubMed ID: 27387641)
1. Therapeutic options in papillary thyroid carcinoma: current guidelines and future perspectives.
Scott E; Learoyd D; Clifton-Bligh RJ
Future Oncol; 2016 Nov; 12(22):2603-2613. PubMed ID: 27387641
[TBL] [Abstract][Full Text] [Related]
2. Remarkable response to radioiodine therapy in a case of metastatic macrofollicular variant of papillary thyroid carcinoma.
Marques P; Leite V; Bugalho MJ
Clin Nucl Med; 2014 Feb; 39(2):219-21. PubMed ID: 24368535
[TBL] [Abstract][Full Text] [Related]
3. Is radioiodine ablation necessary for patients with low-risk papillary thyroid carcinoma and tumor >4 cm?
Rosario PW
Eur J Surg Oncol; 2017 Sep; 43(9):1802-1803. PubMed ID: 28743373
[No Abstract] [Full Text] [Related]
4. New therapies for dedifferentiated papillary thyroid cancer.
Fallahi P; Mazzi V; Vita R; Ferrari SM; Materazzi G; Galleri D; Benvenga S; Miccoli P; Antonelli A
Int J Mol Sci; 2015 Mar; 16(3):6153-82. PubMed ID: 25789503
[TBL] [Abstract][Full Text] [Related]
5. Vemurafenib Active in Iodine-Refractory Thyroid Cancer.
Cancer Discov; 2016 Oct; 6(10):OF4. PubMed ID: 27554612
[TBL] [Abstract][Full Text] [Related]
6. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
7. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
Li J; Liang J; Zhao T; Lin Y
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
[TBL] [Abstract][Full Text] [Related]
8. Update on thyroid cancer treatment.
Regalbuto C; Frasca F; Pellegriti G; Malandrino P; Marturano I; Di Carlo I; Pezzino V
Future Oncol; 2012 Oct; 8(10):1331-48. PubMed ID: 23130931
[TBL] [Abstract][Full Text] [Related]
9. Inappropriate Use of Radioactive Iodine for Low-Risk Papillary Thyroid Cancer Is Most Common in Regions with Poor Access to Healthcare.
Marti JL; Davies L; Haymart MR; Roman BR; Tuttle RM; Morris LG
Thyroid; 2015 Jul; 25(7):865-6. PubMed ID: 25963001
[No Abstract] [Full Text] [Related]
10. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
Rothenberg SM; McFadden DG; Palmer EL; Daniels GH; Wirth LJ
Clin Cancer Res; 2015 Mar; 21(5):1028-35. PubMed ID: 25549723
[TBL] [Abstract][Full Text] [Related]
11. TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.
Yang X; Li J; Li X; Liang Z; Gao W; Liang J; Cheng S; Lin Y
J Nucl Med; 2017 Feb; 58(2):258-265. PubMed ID: 27493271
[TBL] [Abstract][Full Text] [Related]
12. Low risk papillary thyroid cancer.
Brito JP; Hay ID; Morris JC
BMJ; 2014 Jun; 348():g3045. PubMed ID: 24935445
[TBL] [Abstract][Full Text] [Related]
13. Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer.
Sacks W; Wong RM; Bresee C; Braunstein GD
Thyroid; 2015 Apr; 25(4):377-85. PubMed ID: 25578116
[TBL] [Abstract][Full Text] [Related]
14. Radioactive iodine use in patients with low- and intermediate-risk papillary thyroid cancer.
Nixon IJ; Ganly I
Future Oncol; 2013 Jul; 9(7):921-3. PubMed ID: 23837752
[No Abstract] [Full Text] [Related]
15. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
Rosário PW; Calsolari MR
Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
[TBL] [Abstract][Full Text] [Related]
16. Differentiated Thyroid Cancer-Treatment: State of the Art.
Schmidbauer B; Menhart K; Hellwig D; Grosse J
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629126
[TBL] [Abstract][Full Text] [Related]
17. The rationale of patients with early-stage papillary thyroid cancer for accepting or rejecting radioactive iodine remnant ablation.
Sawka AM; Rilkoff H; Tsang RW; Brierley JD; Rotstein L; Ezzat S; Asa SL; Segal P; Kelly C; Zahedi A; Gafni A; Goldstein DP
Thyroid; 2013 Feb; 23(2):246-7. PubMed ID: 23009127
[No Abstract] [Full Text] [Related]
18. Should radioactive iodine therapy be administrated in patient of papillary thyroid carcinoma?
Zhao J; Dong J; Sun Q; Wang H; Zhang Z; Zhou X; Liao L
Chin Med J (Engl); 2014; 127(16):3039-40. PubMed ID: 25131255
[No Abstract] [Full Text] [Related]
19. Tyrosine-kinase inhibitors to treat radioiodine-refracted, metastatic, or recurred and progressive differentiated thyroid carcinoma [Review].
Ito Y; Suzuki S; Ito K; Imai T; Okamoto T; Kitano H; Sugitani I; Sugino K; Tsutsui H; Hara H; Yoshida A; Shimizu K
Endocr J; 2016 Jul; 63(7):597-602. PubMed ID: 27210070
[TBL] [Abstract][Full Text] [Related]
20. Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable adjuvant radioactive iodine.
Kluijfhout WP; Pasternak JD; Drake FT; Beninato T; Shen WT; Gosnell JE; Suh I; C L; Duh QY
Surgery; 2017 Jan; 161(1):127-133. PubMed ID: 27855968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
